Evidence map›Paper›PMID 27060084›Full record

Observational studyJournal of neurology2016

Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study.

Sophie Drapier, Alexandre Eusebio, Bertrand Degos, Marc Vérin, Franck Durif, Jean Philippe Azulay, François Viallet, Tiphaine Rouaud, Caroline Moreau, Luc Defebvre and 6 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 3 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Observational
  15. Current and novel infusion therapies for patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2023
    Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 1 country.

Sophie DrapierDepartment of Neurology, EA 4712, University Rennes 1, CHU Pontchaillou, 2 Henri Le Guilloux, 35000, Rennes, France. sophie.drapier@chu-rennes.fr.
Alexandre EusebioDepartment of Neurology and Movement Disorders, APHM Timone University Hospital and Institut de Neurosciences de la Timone, AMU-CNRS UMR 7289, Marseilles, France.
Bertrand DegosDepartment of Neurology, Centre Expert et Inter-Régional de Coordination de la Maladie de Parkinson, Hôpital de la Pitié-Salpêtrière, APHP, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
Marc VérinDepartment of Neurology, EA 4712, University Rennes 1, CHU Pontchaillou, 2 Henri Le Guilloux, 35000, Rennes, France.
Franck DurifDepartment of Movement Disorders and Neurology, CHU Clermont-Ferrand, 58 rue Montalembert, 63003, Clermont-Ferrand, France.
Jean Philippe AzulayDepartment of Neurology and Movement Disorders, APHM Timone University Hospital and Institut de Neurosciences de la Timone, AMU-CNRS UMR 7289, Marseilles, France.
François VialletDepartment of Neurology, University Hospital, Avenue des Tamaris, 13616, Aix-En-Provence, France.
Tiphaine RouaudDepartment of Neurology, CHU Nantes, boulevard Jacques-Monod-Saint-Herblain, 44093, Nantes, France.
Caroline MoreauDepartment of Movement Disorders and Neurology, INSERM U1171, Lille University, CHU Lille, 2, avenue Oscar Lambret, 59037, Lille, France.
Luc DefebvreDepartment of Movement Disorders and Neurology, INSERM U1171, Lille University, CHU Lille, 2, avenue Oscar Lambret, 59037, Lille, France.
Valerie FraixDepartment of Psychiatry and Neurology, CHU Grenoble, Avenue Maquis du Grésivaudan, 38700, La Tronche, France.
Christine TranchantDepartment of Movement Disorders and Neurology, CHU Strasbourg, 1 Place de L Hôpital, 67000, Strasbourg, France.
Karine AndreCLINACT Groupe, Sèvre, France.
Christine Brefel CourbonDepartment of Clinical Pharmacology and Neurosciences, UMR 825 Inserm, University Hospital Toulouse III, 31059, Toulouse, France.
Emmanuel RozeDepartment of Neurology, Assistance Publique Hôpitaux de Paris, Inserm, U 1127, CNRS, UMR 7225, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Universités, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
David DevosDepartment of Medical Pharmacology, INSERM U1171, Lille University, CHU Lille, 2, avenue Oscar Lambret, 59037, Lille, France.
Centre Oscar Lambret · FRHôpital de la Timone · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier du Pays d'Aix · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRCentre Hospitalier Universitaire de Grenoble · FRCentre Hospitalier Universitaire de Rennes · FRHospices Civils de Lyon · FRInserm · FRInstitut Génétique Nantes Atlantique · FRPitié-Salpêtrière Hospital · FRUniversité de Rennes · FRUniversité Fédérale de Toulouse Midi-Pyrénées · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To report on OPTIPUMP, a cohort study, investigating the impact in real-life clinical settings of continuous subcutaneous apomorphine infusion (CSAI) on the quality of life (HRQoL) of patients with Parkinson's disease. OPTIPUMP was a prospective, open-label, observational cohort study involving 30 investigational sites in France. CSAI was proposed as part of routine clinical care to patients aged ≥18 years, in absence of dementia, with a PD diagnosis and based on the presence of motor fluctuations not controlled by oral treatments. The impact of APO-pump on quality of life was evaluated as the difference in PDQ-39 scores between the initiation treatment and the follow-up visit after 6 months' treatment. All adverse events were recorded. Hyper- and hypodopaminergic behavioral tolerance was assessed on the Ardouin Scale of Behavior in Parkinson's Disease. Between September 2011 and January 2013, we enrolled 142 patients: 42 patients were withdrawn due to pump removal (33), death (4), lost of follow-up (4), no available data (1). 100 completed the study. At 6 months, their HRQoL had significantly improved (p = 0.011), as had their total UPDRS score (p < 0.001). Regarding the safety profile, Ardouin scale scores indicated that their hyperdopaminergic behaviors had not increased. CSAI had a favorable impact on HRQoL, with benefits outweighing risks. The analysis of the withdrawn patients highlights the heterogeneity of the use of the pump having an impact on its efficacy and tolerability.

Indexed as

Infusion PumpsQuality of LifeAgedAntiparkinson AgentsApomorphineDopamine AgonistsFemaleFollow-Up StudiesFranceHumansInfusions, SubcutaneousMaleParkinson DiseaseProspective StudiesTreatment OutcomeAntiparkinson AgentsApomorphineDopamine AgonistsApomorphine pumpParkinson’s diseaseQuality of life

Identifiers

PMID27060084
OpenAlexW2329005323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.